Enanta Pharma(ENTA.US)

Last Updated 19:00:00 ET
longbridge loading

Enanta Pharma's RSV Bet And Immunology Ambitions

rttnews·
US
ENTA
+2.30%
US
IBB
+0.10%
US
IHE
+1.26%
rttnews·
US
ENTA
+2.30%
US
IBB
+0.10%
US
IHE
+1.26%

ENANTA PHARMACEUTICALS INC 3Q 2026: Revenue $17.16M, EPS $(0.45) — 10-Q Summary

TradingView·
US
ENTA
+2.30%
US
BIB
+0.05%
US
PBE
+0.11%
TradingView·
US
ENTA
+2.30%
US
BIB
+0.05%
US
PBE
+0.11%

Enanta Pharma shares are trading lower. The company reported Q2 financial results.

benzinga_article·
US
ENTA
+2.30%
benzinga_article·
US
ENTA
+2.30%

Enanta Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 17.16 M

Earnings Watch·
US
ENTA
+2.30%
Earnings Watch·
US
ENTA
+2.30%

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 | ENTA Stock News

StockTitan·
US
ENTA
+2.30%
US
IBB
+0.10%
US
FBT
+0.54%
StockTitan·
US
ENTA
+2.30%
US
IBB
+0.10%
US
FBT
+0.54%

ENTA Q2'26 Earnings: revenue estimate is 17.03M USD

TradingView·
US
ENTA
+2.30%
US
XBI
-0.69%
US
IBB
+0.10%
TradingView·
US
ENTA
+2.30%
US
XBI
-0.69%
US
IBB
+0.10%
© 2026 Longbridge｜Disclaimer